Small company could make a big impact in PAH, says analyst

24 November 2020
gmax_large

Privately-held Chinese company Gmax Biopharm has announced that the first patient has received its humanized monoclonal antibody, GMA301, as part of investigations around the drug’s efficacy for the treatment of pulmonary arterial hypertension (PAH).

As the drug is administered intravenously, and can be dosed on a monthly schedule because of its long-lasting half-life, it may be more convenient and increase therapy compliance for patients, according to GlobalData.

'If similar results are confirmed in human trials, PAH can be turned into a manageable disease'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology